From: Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018)
Patient Group | JIA (N=119) | ALL (N=22) | p |
---|---|---|---|
Age, median (IQR) years | 13.3 (11.3-15.1) | 11.9 (10.2-14.6) | 0.18 |
Gender, girls: boys | 81 : 38 | 9 : 13 | - |
MTXO: MTXSC, n | 45 : 74 | 22 : 0 | - |
MTX dose, median (IQR) mg/m2/week | 9.7 (9.0-10.9) | 14.7 (10.4-20.0) | 0.0002 |
 MTXintol : MTXtol | 9.6 (8.6-11.0) : 10.1 (9.4-10.9)a | 16.3 (14.7-18.4): 13.3 (9.0-21.0)b | a0.22 ; b0.55 |
E-MTX-PG, mean (95% CI) nmol/ mmol Hb | 5.3 (4.9-5.6) | 6.5 (5.5-7.6) | 0.028 |
 MTXintol: MTXtol | 5.4 (5.0-5.9) : 5.0 (4.5-5.5)a | 7.6 (4.5-10.8) : 6.3 (5.0-7.5)b | a0.21; b0.31 |
MTX treatment duration, median (IQR)Â days | 336 (141-766) | 114 (71-254) | 0.0003 |
 MTXintol: MTXtol | 370 (143-766) : 262 (141-629)a | 300 (191-354) : 97 (64-197)b | a0.38 ; b0.033 |